An Open Study for Steroid Resistant, Non-Thymectomized MG Patients
NCT ID: NCT00309101
Last Updated: 2009-06-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
11 participants
INTERVENTIONAL
2006-02-28
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients
NCT00309088
Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
NCT05716035
An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
NCT06759948
Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
NCT02565576
An Exploratory Clinical Study of GC012F Injection for Refractory gMG
NCT06419166
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. tacrolimus
tacrolimus
Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tacrolimus
Oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Those whose MG symptoms are not controlled by the treatment with prednisone
Exclusion Criteria
16 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Astellas Pharma, Inc
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Central Contact
Role: STUDY_CHAIR
Astellas Pharma Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chubu Region, , Japan
Chugoku Region, , Japan
Hokkaido Region, , Japan
Hokuriku Region, , Japan
Kansai Region, , Japan
Kanto Region, , Japan
Kyushu Region, , Japan
Shikoku Region, , Japan
Tohoku Region, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
F506-CL-0602
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.